Restricted accessReview articleFirst published online 2025-6
Predicting telomerase reverse transcriptase promoter mutation in glioma: A systematic review and diagnostic meta-analysis on machine learning algorithms
Glioma is one of the most common primary brain tumors. The presence of the telomerase reverse transcriptase promoter (pTERT) mutation is associated with a better prognosis. This study aims to investigate the TERT mutation in patients with glioma using machine learning (ML) algorithms on radiographic imaging.
Method
This study was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The electronic databases of PubMed, Embase, Scopus, and Web of Science were searched from inception to August 1, 2023. The statistical analysis was performed using the MIDAS package of STATA v.17.
Results
A total of 22 studies involving 5371 patients were included for data extraction, with data synthesis based on 11 reports. The analysis revealed a pooled sensitivity of 0.86 (95% CI: 0.78–0.92) and a specificity of 0.80 (95% CI 0.72–0.86). The positive and negative likelihood ratios were 4.23 (95% CI: 2.99–5.99) and 0.18 (95% CI: 0.11–0.29), respectively. The pooled diagnostic score was 3.18 (95% CI: 2.45–3.91), with a diagnostic odds ratio 24.08 (95% CI: 11.63–49.87). The Summary Receiver Operating Characteristic (SROC) curve had an area under the curve (AUC) of 0.89 (95% CI: 0.86–0.91).
Conclusion
The study suggests that ML can predict TERT mutation status in glioma patients. ML models showed high sensitivity (0.86) and moderate specificity (0.80), aiding disease prognosis and treatment planning. However, further development and improvement of ML models are necessary for better performance metrics and increased reliability in clinical practice.
ChamberlainMCKormanikPA. Practical guidelines for the treatment of malignant gliomas. West J Med1998; 168: 114.
2.
LouisDNPerryAReifenbergerG, et al.The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131: 803–820.
3.
BlackburnEH. Structure and function of telomeres. Nature1991; 350: 569–573.
4.
LiuLLaiSAndrewsLG, et al.Genetic and epigenetic modulation of telomerase activity in development and disease. Gene2004; 340: 1–10.
5.
NonoguchiNOhtaTOhJ-E, et al.TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol2013; 126: 931–937.
6.
BratDJAldapeKColmanH, et al.cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol2018; 136: 805–810.
7.
AritaHNaritaYFukushimaS, et al.Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol2013; 126: 267–276.
8.
KickingerederPSahmFRadbruchA, et al.IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep2015; 5: 1–9.
9.
LeuKOttGALaiA, et al.Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. Journal of neuro-oncology2017; 134: 177–188.
10.
HabibiMAAmaniHMirjaniMS, et al.Predicting the radiological outcome of cerebral aneurysm treatment with machine learning algorithms; a systematic review and diagnostic meta-analysis. Interdisciplinary Neurosurgery2024; 36: 101929. DOI: 10.1016/j.inat.2023.101929.
11.
HabibiMAFakhfouriAMirjaniMS, et al.Prediction of cerebral aneurysm rupture risk by machine learning algorithms: a systematic review and meta-analysis of 18,670 participants. Neurosurg Rev2024; 47: 34. DOI: 10.1007/s10143-023-02271-2.
12.
HabibiMANaseri AlaviSASoltaniFA, et al.Predicting the outcome and survival of patients with spinal cord injury using machine learning algorithms: a systematic review. World Neurosurgery2024; 188: 150–160. DOI: 10.1016/j.wneu.2024.05.103.
13.
HabibiMARashidiFHabibzadehA, et al.Prediction of the treatment response and local failure of patients with brain metastasis treated with stereotactic radiosurgery using machine learning: a systematic review and meta-analysis. Neurosurg Rev2024; 47: 199. DOI: 10.1007/s10143-024-02391-3.
14.
HabibiMAAghaeiFTajabadiZ, et al.The performance of machine learning for prediction of H3K27 M mutation in midline gliomas: a systematic review and meta-analysis. World Neurosurgery2023. DOI: 10.1016/j.wneu.2023.11.061.
15.
HaimOAbramovSShoftyB, et al.Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases. J Neuro Oncol2022; 157: 63–69.
16.
YamashitaKHataeRHiwatashiA, et al.Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagnostic and Interventional Imaging2019; 100: 411–419. DOI: 10.1016/j.diii.2019.02.010.
17.
SunSRenLMiaoZ, et al.Application of MRI-based radiomics in preoperative prediction of NF2 alteration in intracranial meningiomas. Front Oncol2022; 12: 879528.
18.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71. DOI: 10.1136/bmj.n71.
19.
WhitingPFRutjesAWSWestwoodME, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011; 155: 529–536. DOI: 10.7326/0003-4819-155-8-201110180-00009.
20.
LiuZYaoZLiC, et al.A step-by-step guide to the systematic review and meta-analysis of diagnostic and prognostic test accuracy evaluations. Br J Cancer2013; 108: 2299–2303. DOI: 10.1038/bjc.2013.185.
21.
HigginsJ. Cochrane handbook for systematic reviews of interventions. England, UK: The Cochrane Collaboration. Version 5.1. 0, [updated March 2011].
22.
HeJLRenJLNiuGM, et al.Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status. BMC Med Imag2022; 22: 137. DOI: 10.1186/s12880-022-00865-8.
23.
ChoiYSBaeSChangJH, et al.Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics. Neuro Oncol2021; 23: 304–313. DOI: 10.1093/neuonc/noaa177.
24.
HuCFangKDuQ, et al. Diffusion Weighted MRI could precisely predict the pTERT mutation status of GBM using a residual convolutional neural network. medRxiv. 2022.
25.
LiZKaiserLHolzgreveA, et al.Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. Eur J Nucl Med Mol Imag2021; 48: 4415–4425. DOI: 10.1007/s00259-021-05526-6.
26.
AritaHKinoshitaMKawaguchiA, et al.Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Sci Rep2018; 8: 11773. DOI: 10.1038/s41598-018-30273-4.
27.
FangSYFanZWSunZY, et al.Radiomics features predict telomerase reverse transcriptase promoter mutations in World Health organization grade II gliomas via a machine-learning approach. Front Oncol2021; 10: 606741. DOI: 10.3389/fonc.2020.606741.
28.
FukumaRYanagisawaTKinoshitaM, et al.Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep2019; 9: 56767. DOI: 10.1038/s41598-019-56767-3.
29.
JiangCKongZZhangY, et al.Conventional magnetic resonance imaging–based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology2020; 62: 803–813. DOI: 10.1007/s00234-020-02392-1.
30.
LuoHGZhuangQYWangYY, et al.A novel image signature-based radiomics method to achieve precise diagnosis and prognostic stratification of gliomas. Lab Invest2021; 101: 450–462. DOI: 10.1038/s41374-020-0472-x.
31.
NguyenHDAllaireADiamandisP, et al.A machine learning analysis of a “normal-like” IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets. BMC Med2020; 18: 280. DOI: 10.1186/s12916-020-01748-x.
32.
YamashitaKHataeRHiwatashiA, et al.Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagn Interv Imaging2019; 100: 411-419. DOI: 10.1016/j.diii.2019.02.010.
33.
YanJZhangBZhangST, et al.Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. npj Precis Oncol2021; 5: 72. DOI: 10.1038/s41698-021-00205-z.
34.
CalabreseERudieJDRauscheckerAM, et al.Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. NEURO-ONCOLOGY ADVANCES2022; 4: vdac060. DOI: 10.1093/noajnl/vdac060.
35.
LuJLiXLiH. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas. Clin Radiol2022; 77: E560–E567. DOI: 10.1016/j.crad.2022.04.005.
36.
TianOGWuHWuGY, et al.Noninvasive prediction of TERT promoter mutations in high-grade glioma by radiomics analysis based on multiparameter MRI. BioMed Res Int2020; 2020: 3872314. DOI: 10.1155/2020/3872314.
37.
WangHZhangSXingX, et al.Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas. Cancer Med2023; 12: 2524–2537. DOI: 10.1002/cam4.5097.
38.
PeiLJonesKAShboulZA, et al.Deep neural network analysis of pathology images with integrated molecular data for enhanced glioma classification and grading. Front Oncol2021; 11: Article. DOI: 10.3389/fonc.2021.668694.
39.
KorfiatisPLachanceDParneyI, et al.Evaluation of a deep learning architecture for MRI prediction of IDH, 1P19Q and TERT in glioma patients. Neuro Oncol2018; 20: 64.
40.
LiuSZhangCBQiuXG. Genomic and radiomic landscape of IDH wildtype-TERT promoter mutation in lower-grade gliomas. Neuro Oncol2019; 21: 100.
41.
TakahashiSTakahashiMKinoshitaM, et al.Initial result of develop robust deep learning model for detecting genomic status in gliomas against image differences among facilities. Neuro Oncol2021; 23: vi192. DOI: 10.1093/neuonc/noab196.760.
42.
VerduinMCompterIPrimakovS, et al.Predicting prognosis and cancer hotspot mutations using qualitative MR imaging analysis in glioblastoma. Neuro Oncol2019; 21: vi176. DOI: 10.1093/neuonc/noz175.734.
43.
ZhangHBZhangHWZhangYZ, et al.Deep learning radiomics for the assessment of telomerase reverse transcriptase promoter mutation status in patients with glioblastoma using multiparametric MRI. J Magn Reson Imag2023; 58(5): 1441–1451. DOI: 10.1002/jmri.28671.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
